| Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting K Tsukasaki, O Hermine, A Bazarbachi, L Ratner, JC Ramos, ... Journal of Clinical Oncology 27 (3), 453, 2009 | 591 | 2009 |
| Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting K Tsukasaki, O Hermine, A Bazarbachi, L Ratner, JC Ramos, ... Journal of Clinical Oncology 27 (3), 453, 2009 | 591 | 2009 |
| Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes A Bazarbachi, Y Plumelle, J Carlos Ramos, P Tortevoye, Z Otrock, ... Journal of Clinical Oncology 28 (27), 4177-4183, 2010 | 393 | 2010 |
| EBV MicroRNAs in Primary Lymphomas and Targeting of CXCL-11 by ebv-mir-BHRF1-3 T Xia, A O'Hara, I Araujo, J Barreto, E Carvalho, JB Sapucaia, JC Ramos, ... Cancer research 68 (5), 1436-1442, 2008 | 393 | 2008 |
| Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain J Berenguer, P Ryan, J Rodriguez-Bano, I Jarrín, J Carratala, J Pachón, ... Clinical Microbiology and Infection 26 (11), 1525-1536, 2020 | 357 | 2020 |
| Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma JA Sparano, JY Lee, LD Kaplan, AM Levine, JC Ramos, RF Ambinder, ... Blood, The Journal of the American Society of Hematology 115 (15), 3008-3016, 2010 | 296 | 2010 |
| DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. G Casey, ME Lopez, JC Ramos, SJ Plummer, MJ Arboleda, ... Oncogene 13 (9), 1971-1981, 1996 | 275 | 1996 |
| Revised adult T-cell leukemia-lymphoma international consensus meeting report LB Cook, S Fuji, O Hermine, A Bazarbachi, JC Ramos, L Ratner, ... Journal of Clinical Oncology 37 (8), 677, 2019 | 205 | 2019 |
| Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) J Rodríguez-Baño, J Pachón, J Carratala, P Ryan, I Jarrín, M Yllescas, ... Clinical Microbiology and Infection 27 (2), 244-252, 2021 | 137 | 2021 |
| Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma KA Sarosiek, LE Cavallin, S Bhatt, NL Toomey, Y Natkunam, W Blasini, ... Proceedings of the National Academy of Sciences 107 (29), 13069-13074, 2010 | 104 | 2010 |
| Epidemiology, clinical features, and outcome of HTLV-1–related ATLL in an area of prevalence in the United States L Malpica, A Pimentel, IM Reis, E Gotuzzo, L Lekakis, K Komanduri, ... Blood advances 2 (6), 607-620, 2018 | 102 | 2018 |
| A review of new findings in adult T-cell leukemia–lymphoma: A focus on current and emerging treatment strategies O Hermine, JC Ramos, K Tobinai Advances in therapy 35, 135-152, 2018 | 98 | 2018 |
| Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors S Bayraktar, UD Bayraktar, JC Ramos, A Stefanovic, IS Lossos Journal of neuro-oncology 101, 257-265, 2011 | 94 | 2011 |
| IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma JC Ramos, P Ruiz Jr, L Ratner, IM Reis, C Brites, C Pedroso, GE Byrne Jr, ... Blood 109 (7), 3060-3068, 2007 | 92 | 2007 |
| CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma S Bhatt, BM Ashlock, Y Natkunam, V Sujoy, JR Chapman, JC Ramos, ... Blood, The Journal of the American Society of Hematology 122 (7), 1233-1242, 2013 | 87 | 2013 |
| Infections caused by carbapenemase-producing Enterobacteriaceae: risk factors, clinical features and prognosis JRP Pardo, SS Villar, JCR Ramos, V Pintado Enfermedades infecciosas y microbiologia clinica 32, 41-48, 2014 | 81 | 2014 |
| Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study B Gutiérrez-Gutiérrez, MD Del Toro, AM Borobia, A Carcas, I Jarrín, ... The Lancet infectious diseases 21 (6), 783-792, 2021 | 77 | 2021 |
| Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma S Bhatt, BM Ashlock, NL Toomey, LA Diaz, EA Mesri, IS Lossos, ... The Journal of clinical investigation 123 (6), 2616-2628, 2013 | 75 | 2013 |
| Adult T-cell leukemia/lymphoma development in HTLV-1–infected humanized SCID mice P Banerjee, A Tripp, MD Lairmore, L Crawford, M Sieburg, JC Ramos, ... Blood, The Journal of the American Society of Hematology 115 (13), 2640-2648, 2010 | 69 | 2010 |
| Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma AA Phillips, PA Fields, O Hermine, JC Ramos, BE Beltran, J Pereira, ... haematologica 104 (5), 993, 2019 | 66 | 2019 |
